RxDoctor Payments Data

John Henry, MD

Neurology · Winchester, VANPI 1740205822

Payments from drug & device makers

$1,288in general payments, 2019–2025

Across 60 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$167
  • Supernus Pharmaceuticals, Inc.$166
  • Amgen$164
  • Medtronic$122
  • Sunovion Pharmaceuticals Inc.$92
  • Livanova USA, Inc.$72
  • plus $504 from 15 others

What the payments were for

  • Food & beverage$1,27199%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,288 in reported general payments places this provider in the 45th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$132,309
Medicare patients
707
Services billed
1,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OctagamImmun Globg(Igg)/Malt/Iga Ov5025$671,135
AptiomEslicarbazepine Acetate25$46,680
LamictalLamotrigine28$27,535
Clobazam54$9,377
DilantinPhenytoin Sodium Extended32$6,912
Carbamazepine ErCarbamazepine25$5,584
Rivastigmine22$4,996
Carbidopa-LevodopaCarbidopa/Levodopa143$4,326
Levetiracetam160$3,925
Lacosamide38$3,814
Memantine Hcl111$2,781
Zonisamide57$2,142
Pyridostigmine Bromide36$1,693
Donepezil Hcl191$1,663
Gabapentin87$1,643

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerOctagam, Dilantin$47$678,04857 claims
Sunovion Pharmaceuticals Inc.Aptiom$92$46,68025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 474 neurology providers in Virginia.

Other neurology in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →